Trial
NCT01236573
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
National Institutes of Health Clinical Center (CC)
Collaborators
National Cancer Institute (NCI)
Condition
Skin Cancer
Intervention
Fludarabine
Why stopped
Unexpected toxicities, likely due to TIL/IL-12 \& low % of durable responses.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-11-26